Making transformative medicine accessible to every patient

The Problem

More transformative medicines are reaching the market, but the payment solution is not yet in place.

Gene therapies are changing the lives of patients and families devastated by rare diseases. These medicines offer the remarkable hope of a life-saving, potentially curative treatment for previously untreatable diseases. And with 2,500+ trials in the pipeline and a growth rate of 25% per year, this industry is poised to revolutionize medicine.

However, these high-cost, ultra-rare therapies also pose unique challenges for payers across the world when it comes to coverage and reimbursement. Without a payment solution as innovative as the cures themselves, we anticipate patient access becoming a structural issue within 2-3 years, with the burden ultimately falling upon patients and families.